Application of traditional Chinese medicine composition in preparation of influenza B medicine

Abstract

The invention relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating influenza B. The traditional Chinese medicine composition is characterized by being prepared from prepared radix aconiti carmichaeli, rhizoma zingiberis, honey-fried licorice root, honeysuckle, spina gleditsiae, humulus scandens, pogostemon cablin and pericarpium citri reticulatae. The composition disclosed by the invention can be used for obviously inhibiting the increase of the lung index of mice caused by influenza B virus infection and reducing the content of IL-8 and IL-18 in lung tissue homogenate of infected mice, and has a relatively good treatment effect on influenza B infected pneumonia.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, relates to a new use of a traditional Chinese medicine composition, and specifically relates to an application of the traditional Chinese medicine composition in preparing a medicine for type B influenza. Background Art

[0002] Influenza B is an acute respiratory infectious disease caused by influenza B virus, which is mainly transmitted through air droplets and contact. The disease has obvious poisoning symptoms such as high fever, headache, fatigue, body aches and conjunctivitis, but the symptoms of upper respiratory tract catarrh are mild. Some patients can recover through rest or treatment, but for people with more underlying diseases and poor immunity, if they do not receive treatment, they may develop complications such as primary influenza B virus pneumonia and Reye syndrome. In view of the above problems, the field of traditional Chinese medicine should actively intervene in the prevention and treatment of influenza B and develop prescriptions for the symptoms. Summary of the invention

[0003] According to one aspect of the present invention, there is provided a use of a traditional Chinese medicine composition in the preparation of a drug for influenza B, comprising the following components in parts by mass: 10-30 parts of cooked aconite, 5-15 parts of dried ginger, 20-30 parts of roasted licorice, 10-20 parts of honeysuckle, 10-30 parts of Gleditsia sinensis thorns, 20-45 parts of Ipomoea australis, 10-15 parts of patchouli, and 5-15 parts of tangerine peel.

[0004] In the prescription, aconite root, dried ginger and roasted licorice root are the main drugs, honeysuckle, honeysuckle thorn and five-clawed dragon are the secondary drugs, patchouli is the adjuvant drug, and tangerine peel is the guiding drug. Specifically:

[0005] Cooked aconite, dried ginger, and a large amount of roasted licorice are the main drugs, warming the lower abdomen; Wuzhaolong, also known as Nanqi, nourishes the middle and replenishes qi, and is the minister drug. Together with the three main drugs, they support the positive energy; a large amount of roasted licorice and Wuzhaolong strengthen the spleen and replenish qi, and are used together with the adjuvant drugs Patchouli and Tangerine Peel to aromaticize the evil of dampness and turbidity; honeysuckle clears heat and detoxifies, and expel evil. Wu Jutong "treats the upper Jiao like feathers, and it will not rise unless it is light", so only 10-20 parts of honeysuckle are used; honeysuckle and Gleditsia sinensis are both minister drugs. Wuzhaolong (Nanqi) and Gleditsia sinensis are the main components of Tounong Powder. Gleditsia sinensis and honeysuckle are used together to increase the function of clearing away epidemic toxins and draining pus.

[0006] In some embodiments, the following components are included by mass: 10-20 parts of cooked aconite, 10-15 parts of dried ginger, 20-25 parts of roasted licorice, 10-15 parts of honeysuckle, 10-20 parts of Gleditsia sinensis, 20-30 parts of Ipomoea australis, 10-12 parts of patchouli, and 5-10 parts of tangerine peel.

[0007] In some embodiments, the following components are included by mass: 10-12 parts of cooked aconite, 12-15 parts of dried ginger, 20-22 parts of roasted licorice, 10-12 parts of honeysuckle, 10-12 parts of Gleditsia sinensis, 20-22 parts of Ipomoea australis, 10-12 parts of patchouli, and 5-6 parts of tangerine peel.

[0008] In some embodiments, the following components are included by mass: 10 parts of cooked aconite, 15 parts of dried ginger, 20 parts of roasted licorice, 10 parts of honeysuckle, 10 parts of Gleditsia sinensis, 20 parts of Ipomoea australis, 10 parts of patchouli, and 5 parts of tangerine peel.

[0009] In some embodiments, the drug further comprises pharmaceutically acceptable adjuvants or additives. Specifically, the pharmaceutically acceptable adjuvants or additives include fillers, disintegrants, lubricants, suspending agents, adhesives, sweeteners, flavoring agents, preservatives, matrices, including but not limited to starch, lactose, glucose, sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose, malt, gelatin, polyols (such as propylene glycol, glycerol, mannitol), compressed tablets, etc., to help improve the stability of the pharmaceutical composition or increase the activity, or produce an acceptable taste or smell in the case of oral administration.

[0010] In some embodiments, the aforementioned composition can be prepared into granules, tablets, capsules, pills, oral solutions, oral suspensions or oral emulsions using existing traditional Chinese medicine preparation methods, thereby facilitating clinical administration.

[0011] The preparation method of the traditional Chinese medicine composition comprises the following steps: taking cooked aconite root, dried ginger, roasted licorice root, honeysuckle, thorn of Gleditsia sinensis, five-clawed dragon, patchouli, and tangerine peel, adding 8 to 12 times of water equivalent to the total mass of the raw materials, heating to boiling, maintaining a slight boiling for 1 to 2 hours, and obtaining a first decoction and medicinal residues after separation; a second time, taking the medicinal residues obtained after the first decoction, adding 6 to 10 times of water equivalent to the total mass of the raw materials, heating to boiling, maintaining a slight boiling for 1 to 2 hours, and obtaining a second decoction and medicinal residues after separation; combining the first decoction and the second decoction to obtain a decoction, and reducing the pressure on the decoction filtrate to concentrate it to obtain a clear paste, and crushing it.

[0012] According to another aspect of the present invention, there is provided a use of any of the aforementioned Chinese medicine compositions in the preparation of a medicament for treating influenza B pneumonia.

[0013] When the present invention is used as a drug for treating influenza B, an oral solution can be used. Severe patients are given one dose per day, divided into 2-3 oral or nasogastric administrations, once every 6-8 hours; critically ill patients are given two doses per day, divided into two oral or nasogastric administrations in the morning and evening, once every 8-12 hours; mild patients are given one dose per day, orally or nasogastric administration. Each dose is 150-250 ml.

[0014] When the medicine of the present invention is in the form of granules or tablets, the dosage is converted into a decoction piece dosage and then taken orally.

[0015] The composition of the invention can significantly reduce the lung index of infected rats and reduce the contents of IL-8 and IL-18 in tissue homogenate. DETAILED DESCRIPTION

[0016] As mentioned above, the present invention aims to provide a use of a Chinese medicine composition in the preparation of a drug for influenza B. The following will be described in detail in conjunction with the content of a specific experiment.

[0017] The following experiments, if no specific conditions are specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The APIs or excipients, reagents or instruments used, if the manufacturer is not specified, are all conventional products that can be purchased commercially. Unless otherwise specified, all percentages, ratios, proportions or parts are by weight.

[0018] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the present invention.

[0019] Example 1 Preparation of Chinese medicine composition

[0020] Take 10 kg of cooked aconite, 15 kg of dried ginger, 20 kg of roasted licorice, 10 kg of honeysuckle, 10 kg of Gleditsia sinensis, 20 kg of Ipomoea australis, 10 kg of Patchouli, and 5 kg of dried tangerine peel, add 8 times the total mass of water of the raw materials, heat to boiling, keep slightly boiling for 1 hour, and separate to obtain the first decoction and residue; for the second time, take the residue obtained after the first decoction, add 8 times the total mass of water of the raw materials, heat to boiling, keep slightly boiling for 1 hour, and separate to obtain the second decoction and residue; combine the first decoction and the second decoction to obtain a decoction, reduce the pressure and concentrate the decoction filtrate to obtain a clear paste, grind it into fine powder to obtain a traditional Chinese medicine composition, add maltodextrin, mix well, and granulate to obtain traditional Chinese medicine composition granules.

[0021] Experimental Example 2 Therapeutic Effect of Chinese Medicine Composition on Pneumonia Model of Mice Infected with Influenza B Virus 1. Experimental Materials

[0022] 1.1 Animals

[0023] BALB / c mice, SPF grade, 60 mice, weighing 18-20 g, half male and half female.

[0024] Rearing environment: room temperature 20-26℃, relative humidity controlled at 40-70%. Males and females were reared in separate cages, 5 per cage / sex / group.

[0025] 1.2 Drugs

[0026] The Chinese medicine composition prepared in Example 1, Jiangsu Kangyuan Pharmaceutical Co., Ltd.;

[0027] Ribavirin tablets: Hubei Renyue Pharmaceutical Co., Ltd.;

[0028] Ether: Nanjing Chemical Reagent Co., Ltd.

[0029] 1.3 Instruments

[0030] Electronic balance (Sartorius Scientific Instruments, model BS224S); Electronic balance (G&G, model TC3K).

[0031] 2. Dosage design

[0032] The daily dosage of the Chinese medicine composition is 100g of crude drug / day. According to the body surface area conversion method, the equivalent dose for mice is 100g / 60kg*12.3=20.5g of crude drug / kg. According to the 1 / 2:1:2 dosing method, the low dose is 10.3g of crude drug / kg, the medium dose is 20.5g of crude drug / kg, and the high dose is 41.0g of crude drug / kg. Oral administration, 0.2mL / 10g, once a day.

[0033] The daily dosage of ribavirin tablets is 450 mg / day. According to the body surface area conversion method, the equivalent dose for mice is 450 mg / 60 kg*12.3=92.3 mg / kg.

[0034] 3. Experimental Methods

[0035] BALB / c mice were adaptively fed for 3 days and allowed to eat feed and water freely. They were randomly divided into a normal control group, a model control group, a ribavirin tablet control group, and a high-, medium-, and low-dose group of the Chinese medicine composition according to their body weight, with 10 mice in each group.

[0036] Take influenza B virus liquid and dilute it with normal saline according to 10 LD50.

[0037] Except for the normal control group, mice were lightly anesthetized with ether and infected with diluted influenza B virus drops in the nose, 50 μL per mouse. The normal control group was dripped with an equal amount of saline. The drug was administered once 1 day before virus infection, and mice were infected on the second day after the first administration. The drug was administered again 3 hours after infection. Each administration group was gavaged at 0.2 mL / 10 g each time, once a day, for 5 consecutive days; the normal control group and the model control group were given distilled water under the same conditions. The mice were weighed and killed on the 7th day after infection, and the lungs were dissected and weighed. The organ index was calculated, and the lung tissue was stored in EP tubes at -80 ° C for the detection of inflammatory factors.

[0038] Organ index (%) = organ wet weight (g) / body weight (g) × 100;

[0039] 4. Statistical methods

[0040] The results were statistically analyzed using t-test.

[0041] 5. Experimental Results

[0042] After mice were infected with the B virus solution, the lung index, IL-8 and IL-18 in the lung tissue of mice were significantly increased compared with the normal control group, with statistical differences (P<0.01); after treatment with the Chinese medicine composition, the lung index, IL-8 and IL-18 in the lung tissue of the high and medium dose groups were significantly reduced compared with the model control group, with statistical differences (P<0.01). See Table 1.

[0043] Table 1: Therapeutic effects on influenza B virus infection mouse pneumonia model

[0044]

[0045] Note: Compared with the normal control group, ## P<0.01; compared with the model control group, **P<0.01.

[0046] 6. Experimental conclusion

[0047] The Chinese medicine composition can significantly inhibit the increase of lung index in mice infected with influenza B virus and reduce the content of IL-8 and IL-18 in lung tissue, indicating that the Chinese medicine composition has a certain therapeutic effect on influenza B virus and pneumonia mice caused by it.

[0048] The above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. Use of a Chinese medicine composition in the preparation of a drug for influenza B, characterized in that: The traditional Chinese medicine composition is prepared from the following components: 10-30 parts of cooked aconite root, 5-15 parts of dried ginger, 20-30 parts of roasted licorice root, 10-20 parts of honeysuckle, 10-30 parts of Gleditsia sinensis thorns, 20-45 parts of Ipomoea australis, 10-15 parts of patchouli, and 5-15 parts of tangerine peel.

2. The use according to claim 1, characterized in that: The invention is prepared from the following raw material components by weight: 10-20 parts of cooked aconite root, 10-15 parts of dried ginger, 20-25 parts of roasted licorice root, 10-15 parts of honeysuckle, 10-20 parts of Gleditsia sinensis thorns, 20-30 parts of Ipomoea australis, 10-12 parts of patchouli and 5-10 parts of dried tangerine peel.

3. The use according to claim 1, characterized in that: The traditional Chinese medicine composition is prepared from the following components by weight: 10-12 parts of cooked aconite root, 12-15 parts of dried ginger, 20-22 parts of roasted licorice root, 10-12 parts of honeysuckle, 10-12 parts of Gleditsia sinensis thorns, 20-22 parts of Ipomoea australis, 10-12 parts of patchouli, and 5-6 parts of tangerine peel.

4. The use according to claim 1, characterized in that: The invention is prepared from the following raw material components by weight: 10 parts of cooked aconite root, 15 parts of dried ginger, 20 parts of roasted licorice root, 10 parts of honeysuckle, 10 parts of Gleditsia sinensis thorns, 20 parts of Ipomoea australis, 10 parts of patchouli, and 5 parts of tangerine peel.

5. The use according to any one of claims 1 to 4, characterized in that: The drug also includes pharmaceutically acceptable excipients or additives medically acceptable excipients.

6. The use according to claim 5, characterized in that The pharmaceutically acceptable adjuvants or additives include fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, and bases.

7. The application according to claim 6, characterized in that: The dosage form for the drug includes an oral dosage form, an injection dosage form or an external dosage form.

8. The use according to claim 4, characterized in that: The pharmaceutical composition is in the form of granules, tablets, capsules, pills, oral solutions, oral suspensions or oral emulsions.

9. The use according to claims 1-4, characterized in that: The preparation method of the traditional Chinese medicine composition comprises the following steps: taking cooked aconite root, dried ginger, roasted licorice root, honeysuckle, thorn of Gleditsia sinensis, five-clawed dragon, patchouli, and tangerine peel, adding 8 to 12 times of water equivalent to the total mass of the raw materials, heating to boiling, maintaining a slight boiling for 1 to 2 hours, and obtaining a first decoction and medicinal residues after separation; a second time, taking the medicinal residues obtained after the first decoction, adding 6 to 10 times of water equivalent to the total mass of the raw materials, heating to boiling, maintaining a slight boiling for 1 to 2 hours, and obtaining a second decoction and medicinal residues after separation; combining the first decoction and the second decoction to prepare a decoction, and reducing the pressure to concentrate the decoction filtrate to obtain a clear paste, and crushing it.

10. Use of a Chinese medicine composition in preparing a drug for treating influenza B pneumonia, characterized in that: The traditional Chinese medicine composition is prepared from the following components: 10-30 parts of cooked aconite root, 5-15 parts of dried ginger, 20-30 parts of roasted licorice root, 10-20 parts of honeysuckle, 10-30 parts of Gleditsia sinensis thorns, 20-45 parts of Ipomoea australis, 10-15 parts of patchouli, and 5-15 parts of tangerine peel.

Images